The DPP-4 inhibitor Onglyza® (saxagliptin), has received a positive recommendation from the All Wales Medicines Strategy Group (AWMSG) for use as part of a triple therapy treatment combination for type 2 diabetes within NHS Wales. Saxagliptin is recommended in adult type 2 diabetes patients aged 18 years and older, in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate blood glucose control.
There are approximately 144,000 people with diagnosed type 2 diabetes in Wales and possibly a further 59,400 people who are undiagnosed. In Wales alone it is anticipated that 6,300 new cases of type 2 diabetes are diagnosed each year. Around 12% of type 2 diabetes patients are currently taking triple therapy regimens, with approximately 40% of these taking a combination of metformin, a sulphonylurea and a DPP-4 inhibitor.
“The AWMSG decision to recommend access to saxagliptin for use in triple therapy is good news for patients and is an important step in tackling the growing burden of type 2 diabetes in Wales. Diabetes is a complex disease and a variety of tailored treatment combinations are required to meet patients’ individual needs. This latest recommendation further expands our treatment options on the NHS in Wales.” said John Wakeling, GP at Ely Bridge surgery, Cardiff, Wales.
The AWMSG triple therapy recommendation follows the triple therapy licence granted by the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in January 2013.